BDTX-4933 free base · Synonyms: BDTX-4933 (formic salt form)

BDTX-4933 is a brain-penetrant, orthosteric RAF inhibitor.

For research use only. Not for human or veterinary use.

Target SGK

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

BDTX-4933 structure

CAS No.: 2803840-82-4

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
5 mg	USD 568.00	BP-02272-5mg	In stock	Get quote
10 mg	USD 855.00	BP-02272-10mg	In stock	Get quote
25 mg	USD 1,343.00	BP-02272-25mg	In stock	Get quote
50 mg	USD 1,986.00	BP-02272-50mg	In stock	Get quote
100 mg	Inquire	BP-02272-100mg	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

BDTX-4933 is a brain-penetrant, orthosteric RAF inhibitor.

Identifiers

SMILES: O=S(NC1=C(F)C=C(C2=NC(NN=C3C)=C3C(OC4CCN(CC4)C)=N2)C=C1)(C5=CC(Cl)=CC=C5F)=O
InChIKey: JYTNHYIPLJUSAJ-UHFFFAOYSA-N

Specifications

MW (average): 548.9930
Formula: C₂₄H₂₃ClF₂N₆O₃S
CAS No.: 2803840-82-4
Physical state: Solid
Color: white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Pure form 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Yoon-Chi Han, Pui Yee Ng, Luisa Shin Ogawa, Shao Ning Yang, Miao Chen, Darlene Romashko, Tai-An Lin, Elizabeth Buck; Abstract A090: Preclinical efficacy of BDTX-4933, a brain-penetrant, orthosteric RAF inhibitor, targeting oncogenic RAF conformation shared by groups of BRAF and upstream driver mutations. Mol Cancer Ther 1 December 2023; 22 (12_Supplement): A090. https://doi.org/10.1158/1535-7163.TARG-23-A090

Same research area

Search Cancer